Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There is a need for alternative therapies for hot flashes, as hormone replacement therapy (HRT) is associated with increased rates of breast cancer and heart disease, and some women fail to respond to HRT. A 32-year-old woman with surgically-induced menopause experienced 20-30 severe hot flashes per day and failed to respond to various formulations of HRT and selective serotonin reuptake inhibitor (SSRI) therapy for 17 years. She markedly responded to gabapentin therapy. Gabapentin, SSRIs, and estrogen may act at different cellular targets in the treatment of hot flashes.
 ...
PMID:Hot flashes refractory to HRT and SSRI therapy but responsive to gabapentin therapy. 1503 36

The objective was to provide an overview of the options for treatment of primary restless legs syndrome (RLS), by analysing the relevant clinical trials for RLS. The patients considered were those affected with primary (or idiopathic) RLS. Levodopa, pramipexole, ropinirole, transdermal rotigotine, pergolide and cabergoline all show clear evidence for efficacy in short-term treatment. Adverse events with these drugs are those usual for dopaminergic agents, and are usually mild and reversible, probably because of the relatively low doses needed. Augmentation, i.e., worsening of RLS symptoms not due to progression of the disease, however, represents a worrisome side effect of dopaminergic drugs, especially levodopa. Ergot-derived dopaminergic agents should also be periodically checked for the possible development of multivalvular heart disease and pleuropulmonary fibrosis. Gabapentin is another drug also having clear evidence for efficacy. In conclusion, dopaminergic agents represent the first line of treatment for idiopathic RLS.
 ...
PMID:The treatment of restless legs syndrome. 1723 34